US Edition
Axiom Space-tested cancer drug advances to clinical trials
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
Singularity of space generates medical advances in the land San José, 28 Jun (elmundo.cr) – The work of the physician and researcher Dr. Abba Zubair combines two passions — medicine and space — for the benefit of astronauts and people on earth. His research in space is shedding discoveries about cancer, strokes, bone loss and more. In this alert, Dr. Zubair answers five questions about his studies in microgravity. 1. What do you expect to achiev…
Axiom Space-tested cancer drug advances to clinical trials
A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials. Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona …
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
To view factuality data please Upgrade to Premium
